Pharma Focus Asia

SK pharmteco Expands Production Capacity

Friday, June 23, 2023

SK pharmteco announced that its subsidiary, Yposkesi has successfully completed the construction of its second industrial bioproduction site for C&GT manufacturing.

The new site specialises in the bioproduction of adeno-associated virus (AAV) and lentiviral vector (LV), viral vectors widely used in cell and gene therapy spanning from clinical to commercial applications.

The facility has been strategically designed to accommodate six Upstream Process (USP) clean rooms and two Downstream Process (DSP) clean rooms. This expansion significantly increases the bioreactor capacity from 2,000 litres to 7,000 litres. As a result, the turnaround time for projects has been reduced from 18 months to 12 months.

The newly completed facility at the Genopole campus is a significant addition to biomanufacturing capabilities for cell and gene therapies (C&GT) in Europe. Spanning 5,000 square metres, the facility has been designed in accordance with the current Good Manufacturing Practises (GMP) guidelines of the US and Europe.

The facility's state-of-the-art design will allow to manufacture advanced therapies more efficiently and cost-effectively in line with their C&GT pipelines and commitments, making these treatments more accessible to patients.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference